TABLE 2.
Incidence of Met129 in clinical specimens, tumor biopsies, and tumor cell linesa
| Specimen no.,b tumor line, or tumor biopsy | EBV strain | Met129 status | Sample source |
|---|---|---|---|
| 26 | B958a-B958 | Positive | Healthy individual PBMC |
| 10 | B958a-B958 | Positive | HIV+ PBMC |
| 19 | B958a-B958 | Positive | HIV+ normal tongue |
| 15 | B958a-B958 | Positive | HIV+ HLP |
| Jijoye BL | B958a-F2 | Negative | EBV+ BL cell line |
| 22 | B958b-F2 | Positive | Healthy individual saliva |
| 23 | B958b-F2 | Positive | Healthy individual saliva |
| 28 | 1-G | Positive | Healthy individual PBMC |
| Raji BL* | 1-G | Negative | EBV+ BL cell line |
| 29 | 2a-G | Positive | Healthy individual saliva |
| 7 | 2a-G | Positive | HIV+ normal tongue |
| 16 | 2a-G | Positive | HIV+ HLP |
| 17 | 2a-G | Negative | HIV+ lymphoma |
| 6 | 2a-F1 | Positive | HIV+ normal tongue |
| 2 | 2a-F1 | Negative | HIV+ HLP |
| 18 | 2a-F1 | Positive | HIV+ lymphoma |
| Akata* | 2a-F1 | Negative | Akata BL cell line |
| CAO* | 2a-F1 | Negative | NPC xenograft |
| Xeno-2117 | 2a-F1 | Negative | NPC xenograft |
| NPC10 | 2a-F1 | Negative | Primary NPC biopsy |
| NPC3* | 2a-F1 | Negative | Primary NPC biopsy |
| NPC6* | 2a-F1 | Negative | Primary NPC biopsy |
| NPC 1510* | 2b-F1 | Negative | Primary NPC biopsy |
| C15* | 2c-C | Negative | NPC xenograft |
| AG876* | 2a-C | Negative | EBV+ BL cell line |
| 20 | 3c-C | Positive | Healthy individual saliva |
| 21 | 3c-D | Negative | Healthy individual saliva |
| 24 | 3c-D | Negative | Healthy individual saliva |
| 8 | 3c-D | Positive | HIV+ normal tongue |
| 1 | 3c-D | Negative | HIV+ HLP |
| 11 | 4-D | Negative | IM saliva |
| 3 | 4-D | Negative | HIV+ HLP |
| 4 | 5-D | Negative | HIV+ HLP |
| NPC30* | 7-H | Negative | Primary NPC biopsy |
| 14 | 8-F3 | Positive | Posttransplant lymphoma |
a
Numbered clinical specimens harbor a single strain of EBV (50), as do shown BL cell lines and NPC biopsies. The strain identity of infecting EBV is shown with its Met129 status. The strain identities, based on C-terminal LMP-1 sequences (50), of several of the tumor isolates listed in Fig. 3 were derived from published sequences, and the status of Met129 for these isolates is included for comparison. *, references for tumor cell lines or biopsies are cited in Fig. 3.
b
Human subjects guidelines of each participating institution were followed in the conduct of this research with human tissues.